The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Influence of pre-analytical time and temperature conditions on serum thromboxane B 2 levels

(2018) J.J.K. van Diemen et al.   THROMBOSIS RESEARCH

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway

(2016) Christina Roaldsnes et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

(2016) A. Alvarez-Larran et al.   HAEMATOLOGICA

Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement

(2016) Giovanna Petrucci et al.   THROMBOSIS AND HAEMOSTASIS

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

(2016) A. Alvarez-Larran et al.   HAEMATOLOGICA

In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes

(2015) Francesco Zaccardi et al.   DIABETES

Platelet progenitors: the hidden drug target

(2015) Bianca Rocca et al.   EUROPEAN HEART JOURNAL

Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011

(2015) Melissa A. Deadmond et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study

(2015) Malin Hultcrantz et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Aspirin response: Differences in serum thromboxane B2 levels between clinical studies

(2015) Charlotte Brun et al.   PLATELETS

How common are myeloproliferative neoplasms? A systematic review and meta-analysis

(2014) Glen J. Titmarsh et al.   AMERICAN JOURNAL OF HEMATOLOGY

In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia

(2014) Isabella Squellerio et al.   THROMBOSIS AND HAEMOSTASIS

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia

(2013) C. Patrono et al.   BLOOD

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union

(2013) Odile Moulard et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target

(2012) S. Pascale et al.   BLOOD

Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients

(2012) Jean-Luc Reny et al.   CIRCULATION

The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes

(2012) B. ROCCA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

(2011) R. Scherber et al.   BLOOD

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

(2011) G Finazzi et al.   LEUKEMIA

Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia

(2011) Jean-Guillaume Dillinger et al.   THROMBOSIS RESEARCH

Protease-Activated Receptor Signaling in Platelets Activates Cytosolic Phospholipase A 2α Differently for Cyclooxygenase-1 and 12-Lipoxygenase Catalysis

(2010) Michael Holinstat et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

(2010) A. Alvarez-Larran et al.   BLOOD

The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy

(2009) A. Dragani et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization

(2009) Andrew L. Frelinger et al.   CIRCULATION

Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays

(2009) Francesca Santilli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

(2009)   LANCET

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

(2008) V. De Stefano et al.   HAEMATOLOGICA